# K060572: Modification to Polarcath Peripheral Dilatation System

- Pathway: 510(k) (Special)
- Applicant: Boston Scientific Corporation
- Decided: Mar 15, 2006 after 9 days
- Product code: DQY (Catheter, Percutaneous)
- Device class: 2
- Regulation: 21 CFR 870.1250
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 1 generation back to K051916 (2005). 1 ancestor in all.
97 later devices descend from it; 1 cites it directly.
0 of 99 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K051916: Polar Cath Peripheral Dilatation System, Cryo Vascular Systems, Inc. (2005) Summary page 2.

## Most influential descendants
- K072283: Dorado Pta Balloon Dilatation Catheter (2007), 96 descendants of its own
- K083657: Conquest Pta Balloon Dilatation Catheter (2008), 44 descendants of its own
- K103459: Vascutrak Pta Dilatation Catheter (2010), 36 descendants of its own
- K082579: Evercross .035 Otw Pta Dilatation Catheter (2008), 35 descendants of its own
- K112182: Angiosculpt Pta Scoring Balloon Catheter (2011), 29 descendants of its own

## Indications for use
The PolarCath Peripheral Dilatation System is indicated to dilate stenoses in the peripheral vasculature (iliac, femoral, popliteal, infrapopliteal, renal and subclavian arteries) and for the treatment of obstructive lesions of polytetrafluoroethylene (PTFE) access grafts or native arteriovenous dialysis fistulae. The PolarCath Peripheral Dilatation System is also indicated for post-deployed stent expansion of self-expanding peripheral vascular stents.

Source page: https://510kreport.com/device/K060572
Methodology: https://510kreport.com/methodology